Obesity Related Glomerulopathy: weighing in the effect of Body Surface Area

Bielopolski Dana; Singh Neha; S Bentur Ohad; Renert-Yuval Yael; MacArthur Robert; S Vasquez Kimberly; S Moftah Dena; D Vaughan Roger; G Kost Rhonda; N Tobin Jonathan

doi:10.1101/2021.03.11.21253278

Abstract

Importance Obesity-related glomerulopathy (ORG), part of the cardio-renal spectrum, has an early reversible stage of hyperfiltration. Early identification in the obese adolescent population provides an opportunity to reverse the damage.

Objective Age-appropriate formulae for estimated glomerular filtration rate (eGFR), are standardized to ideal body surface area (BSA) and provide assessment of renal function in mL/min/1.73 m² units, may underestimate prevalence of early ORG. We investigated whether adjusting eGFR to actual BSA more readily identifies early ORG.

Design Cross sectional cohort study. Data were collected between 2011-2015 and analysis was performed between January-November 2020.

Setting Electronic health records clinical data base from 12 academic health centers and community health centers in the New York metropolitan area.

Participants 22,417 women and girls ages 12-21 years for whom data of body measurements and renal function were available.

Main Outcome and measures The hypothesis was generated using previously collected health record data. eGFR was calculated in two ways: BSA-standardized eGFR according to KDIGO recommended formula; and Absolute eGFR adjusted to individual BSA. Hyperfiltration was defined above a threshold of 135mL/min/1.73 m² or 135 mL/min, respectively. The prevalence of hyperfiltration according to each formula was assessed in parallel to 24-hour urine creatinine.

Results 22,417 female adolescents mean age 17 with high prevalence of underrepresented populations (32.6% African American, 12.8% Caucasians and 40.4% Hispanic) were evaluated. Serum creatinine values and hyperfiltration rates according to BSA-standardized eGFR were similar,13.4-15.3%, across Body Mass Index (BMI) groups. Prevalence of hyperfiltration determined by Absolute eGFR differed across groups: Underweight – 2.3%; Normal 6.1%; Overweight – 17.4%; Obese – 31.4%. This trend paralleled the rise in 24-hour urine creatinine across BMI groups.

Conclusions and relevance Absolute eGFR more readily identifies early ORG compared to currently used formulae, which are adjusted to an archaic value of a BSA, not representative of current population BMI measures. The high proportion of underrepresented populations in this study accounts for the higher-than-expected obesity rates and should raise awareness for missed opportunities for screening, early diagnosis, and intervention particularly in young Black adults.

Question Do the currently recommended formulae estimating GFR reliably predict hyperfiltration due to Obesity Related Glomerulopathy (ORG)?

Findings Renal function in relation to BMI was evaluated in a cohort of 22,417 adolescents from the New York metropolitan. Serum creatinine values and BSA-standardized eGFR (mL/min/1.73m²) were similar across BMI groups, and as a result, hyperfiltration rates were also similar. However, Absolute eGFR (mL/min) adjusted to individual BSA, created a positive trend across BMI groups similar to urine creatinine.

Meaning Absolute eGFR better reflects the prevalence of hyperfiltration due to Obesity Related Glomerulopathy providing an opportunity for early intervention and damage reversal.

Competing Interest Statement

Jonathan N. Tobin: NIH-NCI: Payments or Remuneration, Bio-Ascend LLC/Regional Cancer Care Associates: Payments or Remuneration, Reimbursed or Sponsored, Travel, AstraZeneca: Board of Directors Compensation, Payments or Remuneration, Reimbursed or Sponsored Travel. Clinical Directors Network, Inc. (CDN): Board of Directors Compensation, Payments or Remuneration, Reimbursed or Sponsored Travel

Funding Statement

This project was supported by: (1) The Sackler Center for Biomedicine and Nutrition Research at The Rockefeller University; (2) The Sackler Institute for Nutrition Science at The New York Academy of Sciences; (3) N2: Building a Network of Safety-Net PBRNs (AHRQ 1-P30-HS-021667); (4) The National Center for Advancing Translational Sciences grants to the Rockefeller University Center for Clinical and Translational Science, #UL1TR001866 and UL1 TR000043. (5) Patient-Centered Outcomes Research Institute (PCORI); contract number CDRN-1306-03961. (6) The Rockefeller University Clinical Scholar Endowment Fund.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Data extraction and transmission were reviewed and approved, and a waiver of informed consent for analyzing de-identified data was granted by the Institutional Review Boards at Clinical Directors Network (CDN), BRANY (Biomedical Research Alliance of New York), and the Rockefeller University.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data have been provided by the INSIGHT Clinical Research Network and can be made available upon request. The INSIGHT Governance Board will review each request.